
The study investigate the effectiveness and safety of teneligliptin over placebo in patients with type 2 diabetes (T2D) inadequately controlled by triple therapy. Results revealed that teneligliptin could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs.
Like
Save
Share